Ramasamy Sakthivel

Learn More
BACKGROUND Therapeutic potential was evaluated in a rat model of myocardial infarction using nanofiber-expanded human cord blood derived hematopoietic stem cells (CD133+/CD34+) genetically modified with VEGF plus PDGF genes (VIP). METHODS AND FINDINGS Myocardial function was monitored every two weeks up to six weeks after therapy. Echocardiography(More)
  • 1